BAYER AG
🇩🇪Germany
- Country
- 🇩🇪Germany
- Ownership
- Public
- Established
- 1863-08-01
- Employees
- 99.7K
- Market Cap
- $30.1B
- Website
- http://www.bayer.com
Ultravist: Safety and Efficacy in Computed Tomography of Head and Body
Phase 3
Completed
- Conditions
- Interventions
- First Posted Date
- 2005-10-26
- Last Posted Date
- 2014-02-28
- Lead Sponsor
- Bayer
- Target Recruit Count
- 435
- Registration Number
- NCT00244140
Extension of Prior Study Evaluating Safety and Tolerability of Two Doses of Betaseron® to Treat Relapsing-remitting Multiple Sclerosis
Phase 2
Completed
- Conditions
- Interventions
- First Posted Date
- 2005-10-12
- Last Posted Date
- 2014-05-08
- Lead Sponsor
- Bayer
- Target Recruit Count
- 63
- Registration Number
- NCT00235989
Safety and Efficacy of SH T00660AA in Treatment of Endometriosis
- First Posted Date
- 2005-09-23
- Last Posted Date
- 2014-01-09
- Lead Sponsor
- Bayer
- Target Recruit Count
- 168
- Registration Number
- NCT00225186
Efficacy and Safety of SH T00660AA in Treatment of Endometriosis
Phase 3
Completed
- Conditions
- Interventions
- First Posted Date
- 2005-09-23
- Last Posted Date
- 2010-04-23
- Lead Sponsor
- Bayer
- Target Recruit Count
- 198
- Registration Number
- NCT00225199
Pearl Index Study With Low Dose Combined Oral Contraceptive
- First Posted Date
- 2005-09-22
- Last Posted Date
- 2015-04-03
- Lead Sponsor
- Bayer
- Target Recruit Count
- 840
- Registration Number
- NCT00220324
Assessment of Long Term Treatment With Testosterone Undecanoate in Males With Hypogonadism
- First Posted Date
- 2005-09-22
- Last Posted Date
- 2014-12-30
- Lead Sponsor
- Bayer
- Target Recruit Count
- 96
- Registration Number
- NCT00220298
Study for Evaluation of Efficacy and Safety of SH L 749 to Indolent B-cell Non-Hodgkin's Lymphoma
Phase 2
Completed
- Conditions
- Interventions
- First Posted Date
- 2005-09-22
- Last Posted Date
- 2014-12-30
- Lead Sponsor
- Bayer
- Target Recruit Count
- 45
- Registration Number
- NCT00220285
Efficacy and Safety Study in Postmenopausal Women to Determine the Lowest Effective Dose for Relief of Moderate to Severe Hot-Flushes
Phase 4
Completed
- Conditions
- Interventions
- First Posted Date
- 2005-09-21
- Last Posted Date
- 2009-05-29
- Lead Sponsor
- Bayer
- Target Recruit Count
- 425
- Registration Number
- NCT00206622
Betaseron 16-Year Long-Term Follow-Up (LTF) in Patients With Relapsing-Remitting Multiple Sclerosis
- First Posted Date
- 2005-09-21
- Last Posted Date
- 2012-11-22
- Lead Sponsor
- Bayer
- Target Recruit Count
- 432
- Registration Number
- NCT00206635
An Efficacy and Safety Comparison Study of Two Marketed Drugs in Patients With Relapsing-remitting MS
Phase 4
Completed
- Conditions
- Interventions
- First Posted Date
- 2005-09-21
- Last Posted Date
- 2014-12-31
- Lead Sponsor
- Bayer
- Target Recruit Count
- 271
- Registration Number
- NCT00206648
© Copyright 2024. All Rights Reserved by MedPath